---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-25-000062"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:17:32.027555+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics launches VIZZ eye drop for presbyopia in U.S.; samples shipped

## Summary
- VIZZ (aceclidine 1.44%) first FDA-approved aceclidine-based eye drop for presbyopia, now commercially available.
- Professional sample distribution to optometrists and ophthalmologists initiated nationwide.
- Commercial product shipments to consumers via ePharmacy starting October; broad availability by mid-Q4 2025.
- 93% of Phase 3 CLARITY trial participants achieved 20/40 near vision within 30 minutes, lasting up to 10 hours.
- Addresses ~128 million U.S. adults with blurry near vision; CEO calls it a 'Category of One'.

## SEC filing metadata
- accession: 0001815776-25-000062
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000062/0001815776-25-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000062/lenz-20250930.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-25-000062
- JSON: https://secwatch.observer/filing/0001815776-25-000062.json
- Plain text: https://secwatch.observer/filing/0001815776-25-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.